Irinotecan combined with bolus 5-fluorouracil and folinic acid for metastatic colorectal cancer: Is this really a dangerous treatment?

Journal of Chemotherapy

Volumn 16, Issue 5, 2004, Pages 487-490

  Idelevich, E ^a   Man, S ^b   Lavrenkov, K ^b   Gluzman, A ^b   Geffen, D B ^b   Shani, A ^a  

^a KAPLAN MEDICAL CENTER   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Chemotherapy; Colorectal cancer; Irinotecan

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BOLUS INJECTION; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; VOMITING;

EID: 8544274454     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2004.16.5.487     Document Type: Article

References (12)

1. Rothenberg M, Meropol N, Poplin E, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19: 3801-3807.
2. Vanhoefer U, Harstrick A, Achterrath W et al. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001; 19: 1501-1518.
3. Advanced colorectal cancer meta - analysis project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
4. Armand JP, Ducreux M, Mahjoubi M et al. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer 1995; 31 A: 1283-1287.
5. Saltz L, Cox J, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905-914.
6. Douillard J, Cunningham D, Roth A, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000; 355: 1041-1047.
7. Abigerges D, Armand JP, Chabot GG, et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamid to control diarrhea. J Natl Cancer Inst 1994; 11: 196-197.
8. Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, et al. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer 1999; 35: 54-59.
9. Sargent D, Niedzwiecki D, O'Connell M, et al. Recommendation for caution with irinotecan, fluorouracil and leucovorin for colorectal cancer. N Engl J Med 2001; 345: 144-145.
10. Elfring G, Emanuel D, Rostagi R, et al. Patterns of use and mortality in community oncology practice setting among patients receiving first-line weekly bolus irinotecan/5-fluorouracil/leucovorin (IFL) for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2002; 21: 133a, (abstr 530).
11. Goldberg RM, Morton RF, Sargent DJ, et al. N9741 oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (FU)/leucovorin (LV) or oxal + CPT-11in advanced colorectal cancer (CRC). Initial toxicity and response data from GI Intergroup study. Proc Am Soc Clin Oncol 2002; 21: 128a, (abstr 511).
12. Toumigand C, Louvet C, Quinaux E, et al. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a phase III study. Proc Am Soc Clin Oncol 2001; 20: 124a, (abstr 494).